Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 16/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21247153 | 0.85 | PTPN1 (0.55) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL21250161 | 0.84 | SMN1; SMN2 (0.65) | CFTRALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21247352 | 0.83 | CFTR (0.51) | CFTRALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21247129 | 0.82 | CFTR (0.47) | CFTRALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21247233 | 0.80 | PTPN1 (0.53) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL21261019 | 0.79 | RAB7A (0.58) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL21247403 | 0.79 | CFTR (0.51) | CFTRALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21247552 | 0.78 | CFTR (0.51) | CFTRALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21260701 | 0.77 | MEN1 (0.67) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL21261146 | 0.77 | MAPT (0.46) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749658-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | claimed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | claimed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | claimed |
| US-11603368-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-03-14 | — | — | US | disclosed |
| EP-3749658-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | CFTR 2739/4885ALDH1A1 2143/4885MAPT 2107/4885 |
| US-11603368-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | CFTR 2739/4885ALDH1A1 2143/4885MAPT 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.